Citigroup Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Stock analysts at Citigroup initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage set a "neutral" rating and a $895.00 price target on the biopharmaceutical company's stock. Citigroup's price target indicates a potential upside of 12.34% from the stock's previous close.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, Leerink Partners reiterated a "market perform" rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $1,097.14.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $7.64 during trading hours on Thursday, hitting $796.69. 363,296 shares of the company were exchanged, compared to its average volume of 523,364. The stock has a market capitalization of $87.55 billion, a price-to-earnings ratio of 19.90, a P/E/G ratio of 3.10 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $1,000.06 and a 200 day simple moving average of $1,035.67. Regeneron Pharmaceuticals has a 52-week low of $784.96 and a 52-week high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.48% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock valued at $8,595,268,000 after buying an additional 91,956 shares during the last quarter. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after acquiring an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after acquiring an additional 184,561 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock valued at $707,759,000 after acquiring an additional 11,499 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.